| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5871260 | Primary Care Diabetes | 2011 | 7 Pages |
Abstract
New classes of treatments for type 2 diabetes have been developed recently and are now available in the UK. This review aims to summarise key clinical efficacy, tolerability and safety data for these agents, including liraglutide, which has received preliminary review by the National Institute for Clinical Excellence (NICE) and was launched in the UK in 2009.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Anthony H. Barnett,